Forbes

A bankruptcy court has approved the sale of CVS Health’s underperforming Omnicare long-term care pharmacy network to GenieRx in a deal valued at $250 million.

During a tumultuous 13-month tenure at the FDA, Makary pursued a wide range of ambitious initiatives. Going forward, their status under the next commissioner is unclear.

Most Americans support banning food dyes—but what drives diet quality is behavior, marketing and access. Removing dyes won’t fix what’s wrong with how we eat.

Isomorphic, which formed as an Alphabet company in 2021, has a massive cash horde, but it’s tight-lipped on what drugs it might bring to the clinic.

Editing a small number of blood-forming stem cells to encode powerful antibodies turns the immune system into a living drug factory.

In this week’s edition of InnovationRx, we look at the latest on the hantavirus outbreak, using quantum physics for metabolic MRIs, how AI can help fill prescriptions and more.

A public health expert explains why the United States is repeating the same mistake with the Hantavirus response as with COVID-19, particularly with communication and testing.

NVision raises $38 million led by health diagnostics giant Abbott to scale up its groundbreaking cancer imaging system. Next up: using its quantum technology to design new drugs.

Alignment Healthcare is bolstering its C-suite, adding the chairman’s role to CEO John Kao’s duties while promoting executives as the provider of Medicare Advantage grows.

Engineered exosomes that naturally go to brain and kidney cells can deliver gene‑silencing drugs far beyond the liver.

Forus reached $1 billion valuation by dealing with the unglamorous admin work of processing scrips so patients can get the drugs they need.

Dr. Omer Awan details lessons from COVID-19 that should be driving the U.S. response in order to contain the Andes hantavirus outbreak.

Jay Bhattacharya dismissed the test-negative design as 'crap.' The biostatistics literature tells a different story.